Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.
Ted W. Johnson(WorldFish), Helen Y. Zou(Centre for Cancer Biology), Paul Richardson(Pfizer (United States)), Justine L. Lam(Pfizer (United States)), Judy Deal(Pfizer (United States)), Michele McTigue(Pfizer (United States)), Robert S. Kania(RG Biopharma (United States)), Michael R. Collins(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Neal W. Sach(Pfizer (United States)), Simon Bailey(The University of Melbourne), Wenyue Hu(Beijing University of Chinese Medicine), J. Jean Cui(Southern Medical University), Qinhua Huang(Pfizer (United States)), Lars D. Engstrom(Mirati Therapeutics (United States)), Ya‐Li Deng(Pfizer (United States)), Mingying He(Pfizer (United States)), Robert L. Hoffman(Pfizer (United States)), Graham L. Smith(Pfizer (United States)), Cynthia L. Palmer(Pfizer (United States)), Phuong Le, Jacqui Hoffman(Pfizer (United States)), Tod Smeal(Pfizer (United States)), Hieu Lam(Pfizer (United States)), Benjamin J. Burke(Pfizer (United States))
Cited by 4
Related Papers
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
|Cancer Research|2007|750
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382